Robert W. Baird reaffirmed their neutral rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research note released on Monday morning. The brokerage currently has a $125.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms have also commented on TSRO. Oppenheimer Holdings, Inc. set a $199.00 price objective on TESARO and gave the company a buy rating in a research note on Sunday, June 4th. Cann reissued a buy rating and issued a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. FBR & Co cut their target price on shares of TESARO from $200.00 to $195.00 and set a mkt perform rating for the company in a research note on Monday, June 5th. Wedbush upgraded shares of TESARO to an outperform rating and set a $168.00 target price on the stock in a report on Monday, June 5th. Finally, Credit Suisse Group set a $198.00 target price on shares of TESARO and gave the company a buy rating in a report on Monday, June 5th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $170.74.

TESARO (NASDAQ TSRO) opened at 126.82 on Monday. The stock’s market cap is $6.87 billion. The stock’s 50 day moving average price is $121.16 and its 200 day moving average price is $135.93. TESARO has a 52 week low of $96.52 and a 52 week high of $192.94.

TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period in the previous year, the business posted ($1.28) EPS. The business’s quarterly revenue was down 17.6% on a year-over-year basis. On average, analysts forecast that TESARO will post ($8.60) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/tesaro-inc-tsro-receives-neutral-rating-from-robert-w-baird/1604997.html.

In other TESARO news, SVP Martin H. Jr. Huber sold 592 shares of TESARO stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at $823,439.80. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,692 shares of company stock valued at $4,628,976. Corporate insiders own 34.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in shares of TESARO by 5.7% in the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock worth $504,230,000 after acquiring an additional 195,590 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares during the period. State Street Corp raised its stake in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock valued at $163,496,000 after acquiring an additional 177,057 shares during the period. BB Biotech AG raised its stake in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock valued at $122,796,000 after acquiring an additional 53,408 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of TESARO during the 2nd quarter valued at $100,301,000.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.